William G. Kaelin

Broad Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

137h-index67.8kcitations490works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(225), Cancer-related Molecular Pathways(93), Epigenetics and DNA Methylation(78), Renal cell carcinoma treatment(63), RNA modifications and cancer(48)

Publications488 total

10205-CB-7 Preclinical and clinical assessment of salvage chemoradiation after mutant IDH inhibitor treatment in glioma
Neuro-Oncology Advances·2025Open Access
Targeting of HIF2-driven cachexia in kidney cancer
Nature Medicine·2025· 2 citedOpen Access
The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs
Nature Communications·2025· 1 citedOpen Access
119 Endogenous retroviruses as tumor-specific antigens in clear cell renal cell carcinoma: A new avenue for immunotherapy
Regular and Young Investigator Award Abstracts·2025Open Access
TMOD-12. Preclinical and clinical assessment of chemoradiation after mutant IDH inhibitor treatment in IDH-mutant glioma
Neuro-Oncology·2025Open Access
CSIG-36. LEVERAGING GENOMIC ALTERATIONS IN GLIOBLASTOMA MULTIFORME
Neuro-Oncology·2025Open Access
P12.22.A A GENETIC MOUSE MODEL OF IDH-MUTANT GLIOMA RESPONDS TO MUTANT IDH INHIBITION AND REVEALS ENHANCED EFFICACY OF SALVAGE CHEMORADIATION AFTER VORASIDENIB
Neuro-Oncology·2025Open Access
62The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs
The Oncologist·2025Open Access
HIF2-driven PTHrP Causes Cachexia and Hypercalcemia in Kidney Cancer: Treatment with HIF2 Inhibitors
2025Open Access
Making sense of low-complexity domains: The 2025 Lasker Basic Science Award
Proceedings of the National Academy of Sciences·2025· 1 citedOpen Access
Positive Selection Screen for Natural Product β-Catenin Inactivators
2025Open Access
Shirole Fig. S12 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
2025Open Access
Table S8 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
2025Open Access
Table S1 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
2025Open Access
Shirole Fig. S7 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
2025Open Access
Shirole Fig. S8 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
2025Open Access
Table S3 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
2025Open Access
Table S4 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
2025Open Access
Shirole Fig. S15 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
2025Open Access
Table S2 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
2025Open Access
page 1 of 25Next →

Frequent Co-authors

Keiichi Kondo(5), Sabina Signoretti(5), Othon Iliopoulos(5), David M. Livingston(5), Mircea Ivan(4), Haifeng Yang(4), María C. Marín(4), Ronald Conaway(4), Joan Conaway(4), Peppi Koivunen(4), Michael Ohh(3), Nikola P. Pavletich(3), William R. Sellers(3), James A. DeCaprio(3), Takumi Kamura(3), Sung-Woo Lee(3), Meredith S. Irwin(3), Rameen Beroukhim(3), James Brugarolas(2), Wenhua Gao(2)